Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02558348
Title	Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)
Acronym	AL3818
Recruitment	Terminated
Gender	female
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Advenchen Laboratories, LLC
Indications	fallopian tube cancer peritoneum cancer endometrial carcinoma ovarian cancer cervical squamous cell carcinoma
Therapies	Anlotinib
Age Groups:	adult \| senior
Covered Countries	USA